Avertto Medical · raw details

Need: Avertto addresses a critical gap in stroke prevention and care. Despite the knowledge that 80% of strokes are preventable, the lack of effective early detection and monitoring tools leads to high rates of death and disability.

Solution: Avertto's neck device uses neck sensors for monitoring, detecting change, and alerting responsive care. Avertto aims to address the market in two phases: in-patient with an external hospital monitor and home-device with an insertable solution. Unique value proposition- alerting stroke before neuronal injury, enabling treatment with the golden hour.

Business model: is based on incurring revenues without needing to develop a reimbursement rate based on the lucrative high need we are targeting. In the US, Avertto leverages ICU disposable reimbursements up to $5,000, strategically setting a sale price at $847 per patient for up to one week of use. This approach not only makes the product accessible to healthcare providers but also supports quick market infiltration.

Traction (Feb24): Sensors - sensitive passive pressure sensors and a small wireless controller for continuous carotid recording. Algorithm Development: highly accurate first threshold algorithm for detecting large vessel occlusion. Clinical Studies: Completed POC (n= 70; Rabin, Galilee Medical Center in Israel, and VDH in Barcelona); successful space mission astronaut study (n=4; Axiom1). Data: unique and extensive continuous carotid data, including healthy controls, Astronaut data, and clinically signed data. Competitions: finalist at the prestigious Marrakesh Forbes Aviram Competition; first place at the HUJI Asper Prize. Collaborations: Avertto's collaborations with Shaare Zedek, Sheba, and Val d'Hebron, Barcelona, Spain. Business Development: contacts with strategic partners (Medtronic, Terumo) and institutional investors (Mayo Clinic, Birmingham Women's Hospital). Regulation: Spain (AEMPS); FDA Class1 to follow up on carotid health (Q2 24).